Showing 1 - 10 of 17,678
Persistent link: https://www.econbiz.de/10011785457
Persistent link: https://www.econbiz.de/10001461562
Persistent link: https://www.econbiz.de/10003931919
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that...
Persistent link: https://www.econbiz.de/10009659550
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that...
Persistent link: https://www.econbiz.de/10014195216
parents from 36 countries globally and their patent holdings in 36 European countries, we provide insight into the … of royalties, R&D incentives, and transfer pricing rules help to explain the patent-location choices of multinationals. …
Persistent link: https://www.econbiz.de/10010511367
This paper investigates the role of patent protection in the global investment decisions of multinational firms. Using … comprehensive firm-level panel data of German multinationals, we investigate how changes in a host country’s patent protection … influence the extensive and intensive margin of foreign direct investment (FDI) decisions. We isolate the effect of patent …
Persistent link: https://www.econbiz.de/10010439153
Persistent link: https://www.econbiz.de/10003603583
Persistent link: https://www.econbiz.de/10011523939
Mittel, die Krankenhäuser mit ihrer lukrativen Vorsorgepraxis und die Pharmaindustrie, für die Krebsmedikamente, deren Preise … und die Pharmaindustrie, mangelnde Transparenz, was Behandlungserfolge und -methoden betrifft. Zugleich weist Lauterbach … verringert. Und er zeigt, was geschehen muss, damit die Pharmaindustrie ihre Forschung wieder in den Dienst des Patienten statt …
Persistent link: https://www.econbiz.de/10014010471